
Verastem (VSTM) Stock Forecast & Price Target
Verastem (VSTM) Analyst Ratings
Bulls say
Verastem is a late-stage development biopharmaceutical company with a strong pipeline of novel anticancer agents focused on RAF/MEK and FAK inhibition. Positive recent clinical data, including a net product revenue beat in 2Q26 and the strengthening of their balance sheet, suggest strong potential for future growth and profitability. The company's emphasis on targeting critical signaling pathways in cancer, such as RAF/MEK and FAK inhibition, along with its focus on advancing new medicines for patients battling cancer, make it an attractive investment for the future.
Bears say
Verastem is facing challenges with market saturation and high competition due to the presence of several other biopharmaceutical companies in the cancer treatment sector. Despite an increase in net product revenue in the past quarter, the company has not yet reached financial self-sustainability and relies heavily on non-dilutive financing and milestone payments for funding. Furthermore, the upcoming confirmatory Phase 3 study for Avmapki and Fakzynja is not expected to yield topline data until mid-2027, potentially causing further delays and hindering the company's growth potential.
This aggregate rating is based on analysts' research of Verastem and is not a guaranteed prediction by Public.com or investment advice.
Verastem (VSTM) Analyst Forecast & Price Prediction
Start investing in Verastem (VSTM)
Order type
Buy in
Order amount
Est. shares
0 shares